

# **Cholangiocarcinoma Therapeutics Market Size, Trends, Analysis, and Outlook By Treatment (Chemotherapy (Gemcitabine, Cisplatin, Oxaliplatin, Capecitabine, 5-FU), Targeted Therapy (Pemigatinib, Infigratinib, Ivosidenib), Immunotherapy), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), by Region, Country, Segment, and Companies, 2024-2030**

<https://marketpublishers.com/r/C431599E232DEN.html>

Date: March 2024

Pages: 190

Price: US\$ 3,980.00 (Single User License)

ID: C431599E232DEN

## **Abstracts**

The global Cholangiocarcinoma Therapeutics market size is poised to register 9.56% growth (CAGR) from 2024 to 2030, presenting significant growth prospects for companies operating in the industry. The industry study analyzes the global Cholangiocarcinoma Therapeutics market By Treatment (Chemotherapy (Gemcitabine, Cisplatin, Oxaliplatin, Capecitabine, 5-FU), Targeted Therapy (Pemigatinib, Infigratinib, Ivosidenib), Immunotherapy), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies).

The future of cholangiocarcinoma therapeutics is characterized by advancements in precision medicine, targeted therapies, and immunotherapy strategies aimed at improving treatment outcomes for this aggressive and often challenging-to-treat cancer. Key trends include the development of molecularly targeted agents, such as fibroblast growth factor receptor (FGFR) inhibitors and isocitrate dehydrogenase (IDH) inhibitors, which selectively target key driver mutations and signaling pathways implicated in cholangiocarcinoma pathogenesis, offering promising avenues for personalized treatment approaches. Additionally, the integration of immune checkpoint inhibitors, chimeric antigen receptor (CAR) T-cell therapies, and cancer vaccines aims to harness

the patient's immune system to recognize and eradicate tumor cells, enhancing antitumor immune responses and improving overall survival in advanced-stage cholangiocarcinoma patients. Moreover, the customization of treatment regimens, combination therapies, and multidisciplinary care approaches based on tumor molecular profiling, disease stage, and patient-specific factors drives personalized approaches and optimization of therapeutic outcomes, addressing the heterogeneity and complexity of cholangiocarcinoma biology and treatment response. Furthermore, the exploration of adjuvant and neoadjuvant treatment strategies, including locoregional therapies, radioembolization, and precision radiation techniques, offers new opportunities for improving local disease control, prolonging survival, and enhancing quality of life for patients with cholangiocarcinoma. Overall, these advancements in cholangiocarcinoma therapeutics offer hope for improved outcomes and better quality of life for patients with this devastating disease, highlighting the importance of continued research and innovation in the field..

## Cholangiocarcinoma Therapeutics Market Drivers, Trends, Opportunities, and Growth Opportunities

This comprehensive study discusses the latest trends and the most pressing challenges for industry players and investors. The Cholangiocarcinoma Therapeutics market research analyses the global market trends, key drivers, challenges, and opportunities in the industry. In addition, the latest Future of Cholangiocarcinoma Therapeutics survey report provides the market size outlook across types, applications, and other segments across the world and regions. It provides data-driven insights and actionable recommendations for companies in the Cholangiocarcinoma Therapeutics industry.

## Key market trends defining the global Cholangiocarcinoma Therapeutics demand in 2024 and Beyond

The industry continues to remain an attractive hub for opportunities for both domestic and global vendors. As the market evolves, factors such as emerging market dynamics, demand from end-user sectors, a growing patient base, changes in consumption patterns, and widening distribution channels continue to play a major role.

## Cholangiocarcinoma Therapeutics Market Segmentation- Industry Share, Market Size, and Outlook to 2030

The Cholangiocarcinoma Therapeutics industry comprises a wide range of segments and sub-segments. The rising demand for these product types and applications is

supporting companies to increase their investment levels across niche segments. Accordingly, leading companies plan to generate a large share of their future revenue growth from expansion into these niche segments. The report presents the market size outlook across segments to support Cholangiocarcinoma Therapeutics companies scaling up production in these sub-segments with a focus on expanding into emerging countries.

Key strategies adopted by companies within the Cholangiocarcinoma Therapeutics industry

Leading Cholangiocarcinoma Therapeutics companies are boosting investments to capitalize on untapped potential and future possibilities across niche market segments and surging demand conditions in key regions. Further, companies are leveraging advanced technologies to unlock opportunities and achieve operational excellence. The report provides key strategies opted for by the top 10 Cholangiocarcinoma Therapeutics companies.

Cholangiocarcinoma Therapeutics Market Study- Strategic Analysis Review

The Cholangiocarcinoma Therapeutics market research report dives deep into the qualitative factors shaping the market, empowering you to make informed decisions-

**Industry Dynamics:** Porter's Five Forces analysis to understand bargaining power, competitive rivalry, and threats that impact long-term strategy formulation.

**Strategic Insights:** Provides valuable perspectives on key players and their approaches based on comprehensive strategy analysis.

**Internal Strengths and Weaknesses:** Develop targeted strategies to leverage strengths, address weaknesses, and capitalize on market opportunities.

**Future Possibilities:** Prepare for diverse outcomes with in-depth scenario analysis. Explore potential market disruptions, technology advancements, and economic changes.

Cholangiocarcinoma Therapeutics Market Size Outlook- Historic and Forecast Revenue in Three Cases

The Cholangiocarcinoma Therapeutics industry report provides a detailed analysis and outlook of revenue generated by companies from 2018 to 2023. Further, with actual data for 2023, the report forecasts the market size outlook from 2024 to 2030 in three case scenarios- low case, reference case, and high case scenarios.

### Cholangiocarcinoma Therapeutics Country Analysis and Revenue Outlook to 2030

The report analyses 22 countries worldwide including the key driving forces and market size outlook from 2021 to 2030. In addition, region analysis across Asia Pacific, Europe, the Middle East, Africa, North America, and South America is included in the study. For each of the six regions, the market size outlook by segments is forecast for 2030.

### North America Cholangiocarcinoma Therapeutics Market Size Outlook- Companies plan for focused investments in a changing environment

The US continues to remain the market leader in North America, driven by a large consumer base, the presence of well-established providers, and a strong end-user industry demand. Leading companies focus on new product launches in the changing environment. The US economy is expected to grow in 2024 (around 2.2% growth in 2024), potentially driving demand for various Cholangiocarcinoma Therapeutics market segments. Similarly, Strong end-user demand is encouraging Canadian Cholangiocarcinoma Therapeutics companies to invest in niche segments. Further, as Mexico continues to strengthen its trade relations and invest in technological advancements, the Mexico Cholangiocarcinoma Therapeutics market is expected to experience significant expansion, offering lucrative opportunities for both domestic and international stakeholders.

### Europe Cholangiocarcinoma Therapeutics Market Size Outlook-Companies investing in assessing consumers, categories, competitors, and capabilities

The German industry remains the major market for companies in the European Cholangiocarcinoma Therapeutics industry with consumers in Germany, France, the UK, Spain, Italy, and others anticipated to register a steady demand throughout the forecast period, driving the overall market prospects. In addition, the proactive approach of businesses in identifying and leveraging new growth prospects positions the European Cholangiocarcinoma Therapeutics market for an upward trajectory, fostering both domestic and international interest. Leading brands operating in the industry are emphasizing effective marketing strategies, innovative product offerings, and a keen

understanding of consumer preferences.

Asia Pacific Cholangiocarcinoma Therapeutics Market Size Outlook- an attractive hub for opportunities for both local and global companies

The increasing prevalence of indications, robust healthcare expenditure, and increasing investments in healthcare infrastructure drive the demand for Cholangiocarcinoma Therapeutics in Asia Pacific. In particular, China, India, and South East Asian Cholangiocarcinoma Therapeutics markets present a compelling outlook for 2030, acting as a magnet for both domestic and multinational manufacturers seeking growth opportunities. Similarly, with a burgeoning population and a rising middle class, India offers a vast consumer market. Japanese and Korean companies are quickly aligning their strategies to navigate changes, explore new markets, and enhance their competitive edge. Our report utilizes in-depth interviews with industry experts and comprehensive data analysis to provide a comprehensive outlook of 6 major markets in the region.

Latin America Cholangiocarcinoma Therapeutics Market Size Outlook- Continued urbanization and rising income levels

Rising income levels contribute to greater purchasing power among consumers, spurring consumption and creating opportunities for market expansion. Continued urbanization and rising income levels are expected to sustainably drive consumption growth in the medium to long term.

Middle East and Africa Cholangiocarcinoma Therapeutics Market Size Outlook- continues its upward trajectory across segments

Robust demand from Middle Eastern countries including Saudi Arabia, the UAE, Qatar, Kuwait, and other GCC countries supports the overall Middle East Cholangiocarcinoma Therapeutics market potential. Fueled by increasing healthcare expenditure of individuals, growing population, and high prevalence across a few markets drives the demand for Cholangiocarcinoma Therapeutics.

Cholangiocarcinoma Therapeutics Market Company Profiles

The global Cholangiocarcinoma Therapeutics market is characterized by intense competitive conditions with leading companies opting for aggressive marketing to gain market shares. The report presents business descriptions, SWOT analysis, growth

strategies, and financial profiles. Leading companies included in the study are Agios Pharmaceuticals, AstraZeneca Plc, Basilea Pharmaceutica, Decalth Systems, Eisai Pharmaceuticals, F. Hoffmann-La Roche Ltd, Servier Pharmaceuticals, Taiho Oncology, TransThera Sciences, Incyte Corp.

## Recent Cholangiocarcinoma Therapeutics Market Developments

The global Cholangiocarcinoma Therapeutics market study presents recent market news and developments including new product launches, mergers, acquisitions, expansions, product approvals, and other updates in the industry.

## Cholangiocarcinoma Therapeutics Market Report Scope

Parameters: Revenue, Volume Price

Study Period: 2023 (Base Year); 2018- 2023 (Historic Period); 2024- 2030 (Forecast Period)

Currency: USD; (Upon request, can be provided in Euro, JPY, GBP, and other Local Currency)

## Qualitative Analysis

Pricing Analysis

Value Chain Analysis

SWOT Profile

Market Dynamics- Trends, Drivers, Challenges

Porter's Five Forces Analysis

Macroeconomic Impact Analysis

Case Scenarios- Low, Base, High

## Market Segmentation:

*Cholangiocarcinoma Therapeutics Market Size, Trends, Analysis, and Outlook By Treatment (Chemotherapy (Gemcita...*

## By Type

Stationary 3D and 4D Ultrasound Devices

Portable 3D and 4D Ultrasound Devices

## By Display

Color Ultrasound

B/W Ultrasound

## By Portability

Trolley or Cart-Based Ultrasound Systems

Compact/Handheld Ultrasound Systems

Point-of-Pare (PoC) Ultrasound Systems

## By Application

Radiology or General Imaging

Obstetrics or Gynecology

Cardiology

Urology

Vascular

Orthopedic and Musculoskeletal

Pain Management

Others

## By End-User

Hospitals

Surgical Centers and Diagnostic Centers

Maternity Centers

Ambulatory Care Centers

Research and Academia

Others

## Geographical Segmentation:

North America (3 markets)

Europe (6 markets)

Asia Pacific (6 markets)

Latin America (3 markets)

Middle East Africa (5 markets)

## Companies

Agios Pharmaceuticals

AstraZeneca Plc

Basilea Pharmaceutica

Decalth Systems

Eisai Pharmaceuticals



F. Hoffmann-La Roche Ltd

Servier Pharmaceuticals

Taiho Oncology

TransThera Sciences

Incyte Corp

Formats Available: Excel, PDF, and PPT

## Contents

### **1. EXECUTIVE SUMMARY**

- 1.1 Cholangiocarcinoma Therapeutics Market Overview and Key Findings, 2024
- 1.2 Cholangiocarcinoma Therapeutics Market Size and Growth Outlook, 2021- 2030
- 1.3 Cholangiocarcinoma Therapeutics Market Growth Opportunities to 2030
- 1.4 Key Cholangiocarcinoma Therapeutics Market Trends and Challenges
  - 1.4.1 Cholangiocarcinoma Therapeutics Market Drivers and Trends
  - 1.4.2 Cholangiocarcinoma Therapeutics Market Challenges
- 1.5 Competitive Landscape and Key Players
- 1.6 Competitive Analysis- Growth Strategies Adopted by Leading Cholangiocarcinoma Therapeutics Companies

### **2. CHOLANGIOCARCINOMA THERAPEUTICS MARKET SIZE OUTLOOK TO 2030**

- 2.1 Cholangiocarcinoma Therapeutics Market Size Outlook, USD Million, 2021- 2030
- 2.2 Cholangiocarcinoma Therapeutics Incremental Market Growth Outlook, %, 2021-2030
- 2.3 Segment Snapshot, 2024

### **3. CHOLANGIOCARCINOMA THERAPEUTICS MARKET- STRATEGIC ANALYSIS REVIEW**

- 3.1 Porter's Five Forces Analysis
  - \* Threat of New Entrants
  - \* Threat of Substitutes
  - \* Intensity of Competitive Rivalry
  - \* Bargaining Power of Buyers
  - \* Bargaining Power of Suppliers
- 3.2 Value Chain Analysis
- 3.3 SWOT Analysis

### **4. CHOLANGIOCARCINOMA THERAPEUTICS MARKET SEGMENTATION ANALYSIS AND OUTLOOK**

- 4.1 Market Segmentation and Scope
- 4.2 Market Breakdown by Type, Application, and Other Segments, 2021-2030
  - By Type

Stationary 3D and 4D Ultrasound Devices  
Portable 3D and 4D Ultrasound Devices  
By Display  
Color Ultrasound  
B/W Ultrasound  
By Portability  
Trolley or Cart-Based Ultrasound Systems  
Compact/Handheld Ultrasound Systems  
Point-of-Pare (PoC) Ultrasound Systems  
By Application  
Radiology or General Imaging  
Obstetrics or Gynecology  
Cardiology  
Urology  
Vascular  
Orthopedic and Musculoskeletal  
Pain Management  
Others  
By End-User  
Hospitals  
Surgical Centers and Diagnostic Centers  
Maternity Centers  
Ambulatory Care Centers  
Research and Academia  
Others  
4.3 Growth Prospects and Niche Opportunities, 2023- 2030  
4.4 Regional comparison of Market Growth, CAGR, 2023-2030

## **5. REGION-WISE MARKET OUTLOOK TO 2030**

5.1 Key Findings for Asia Pacific Cholangiocarcinoma Therapeutics Market, 2025  
5.2 Asia Pacific Cholangiocarcinoma Therapeutics Market Size Outlook by Type, 2021-2030  
5.3 Asia Pacific Cholangiocarcinoma Therapeutics Market Size Outlook by Application, 2021- 2030  
5.4 Key Findings for Europe Cholangiocarcinoma Therapeutics Market, 2025  
5.5 Europe Cholangiocarcinoma Therapeutics Market Size Outlook by Type, 2021-2030  
5.6 Europe Cholangiocarcinoma Therapeutics Market Size Outlook by Application,

2021- 2030

5.7 Key Findings for North America Cholangiocarcinoma Therapeutics Market, 2025

5.8 North America Cholangiocarcinoma Therapeutics Market Size Outlook by Type, 2021- 2030

5.9 North America Cholangiocarcinoma Therapeutics Market Size Outlook by Application, 2021- 2030

5.10 Key Findings for South America Cholangiocarcinoma Therapeutics Market, 2025

5.11 South America Pacific Cholangiocarcinoma Therapeutics Market Size Outlook by Type, 2021- 2030

5.12 South America Cholangiocarcinoma Therapeutics Market Size Outlook by Application, 2021- 2030

5.13 Key Findings for Middle East and Africa Cholangiocarcinoma Therapeutics Market, 2025

5.14 Middle East Africa Cholangiocarcinoma Therapeutics Market Size Outlook by Type, 2021- 2030

5.15 Middle East Africa Cholangiocarcinoma Therapeutics Market Size Outlook by Application, 2021- 2030

## **6. COUNTRY-WISE MARKET SIZE OUTLOOK TO 2030**

6.1 US Cholangiocarcinoma Therapeutics Market Size Outlook and Revenue Growth Forecasts

6.2 US Cholangiocarcinoma Therapeutics Industry Drivers and Opportunities

6.3 Canada Market Size Outlook and Revenue Growth Forecasts

6.4 Canada Cholangiocarcinoma Therapeutics Industry Drivers and Opportunities

6.6 Mexico Market Size Outlook and Revenue Growth Forecasts

6.6 Mexico Cholangiocarcinoma Therapeutics Industry Drivers and Opportunities

6.7 Germany Market Size Outlook and Revenue Growth Forecasts

6.8 Germany Cholangiocarcinoma Therapeutics Industry Drivers and Opportunities

6.9 France Market Size Outlook and Revenue Growth Forecasts

6.10 France Cholangiocarcinoma Therapeutics Industry Drivers and Opportunities

6.11 UK Market Size Outlook and Revenue Growth Forecasts

6.12 UK Cholangiocarcinoma Therapeutics Industry Drivers and Opportunities

6.13 Spain Market Size Outlook and Revenue Growth Forecasts

6.14 Spain Cholangiocarcinoma Therapeutics Industry Drivers and Opportunities

6.16 Italy Market Size Outlook and Revenue Growth Forecasts

6.16 Italy Cholangiocarcinoma Therapeutics Industry Drivers and Opportunities

6.17 Rest of Europe Market Size Outlook and Revenue Growth Forecasts

6.18 Rest of Europe Cholangiocarcinoma Therapeutics Industry Drivers and

## Opportunities

- 6.19 China Market Size Outlook and Revenue Growth Forecasts
- 6.20 China Cholangiocarcinoma Therapeutics Industry Drivers and Opportunities
- 6.21 India Market Size Outlook and Revenue Growth Forecasts
- 6.22 India Cholangiocarcinoma Therapeutics Industry Drivers and Opportunities
- 6.23 Japan Market Size Outlook and Revenue Growth Forecasts
- 6.24 Japan Cholangiocarcinoma Therapeutics Industry Drivers and Opportunities
- 6.26 South Korea Market Size Outlook and Revenue Growth Forecasts
- 6.26 South Korea Cholangiocarcinoma Therapeutics Industry Drivers and Opportunities
- 6.27 Australia Market Size Outlook and Revenue Growth Forecasts
- 6.28 Australia Cholangiocarcinoma Therapeutics Industry Drivers and Opportunities
- 6.29 South East Asia Market Size Outlook and Revenue Growth Forecasts
- 6.30 South East Asia Cholangiocarcinoma Therapeutics Industry Drivers and Opportunities
- 6.31 Rest of Asia Pacific Market Size Outlook and Revenue Growth Forecasts
- 6.32 Rest of Asia Pacific Cholangiocarcinoma Therapeutics Industry Drivers and Opportunities
- 6.33 Brazil Market Size Outlook and Revenue Growth Forecasts
- 6.34 Brazil Cholangiocarcinoma Therapeutics Industry Drivers and Opportunities
- 6.36 Argentina Market Size Outlook and Revenue Growth Forecasts
- 6.36 Argentina Cholangiocarcinoma Therapeutics Industry Drivers and Opportunities
- 6.37 Rest of South America Market Size Outlook and Revenue Growth Forecasts
- 6.38 Rest of South America Cholangiocarcinoma Therapeutics Industry Drivers and Opportunities
- 6.39 Middle East Market Size Outlook and Revenue Growth Forecasts
- 6.40 Middle East Cholangiocarcinoma Therapeutics Industry Drivers and Opportunities
- 6.41 Africa Market Size Outlook and Revenue Growth Forecasts
- 6.42 Africa Cholangiocarcinoma Therapeutics Industry Drivers and Opportunities

## **7. CHOLANGIOCARCINOMA THERAPEUTICS MARKET OUTLOOK ACROSS SCENARIOS**

- 7.1 Low Growth Case
- 7.2 Reference Growth Case
- 7.3 High Growth Case

## **8. CHOLANGIOCARCINOMA THERAPEUTICS COMPANY PROFILES**

- 8.1 Profiles of Leading Cholangiocarcinoma Therapeutics Companies in the Market

8.2 Business Descriptions, SWOT Analysis, and Growth Strategies

8.3 Financial Performance and Key Metrics

Agios Pharmaceuticals

AstraZeneca Plc

Basilea Pharmaceutica

Decalth Systems

Eisai Pharmaceuticals

F. Hoffmann-La Roche Ltd

Servier Pharmaceuticals

Taiho Oncology

TransThera Sciences

Incyte Corp

## **9. APPENDIX**

9.1 Scope of the Report

9.2 Research Methodology and Data Sources

9.3 Glossary of Terms

9.4 Market Definitions

9.5 Contact Information

## I would like to order

Product name: Cholangiocarcinoma Therapeutics Market Size, Trends, Analysis, and Outlook By Treatment (Chemotherapy (Gemcitabine, Cisplatin, Oxaliplatin, Capecitabine, 5-FU), Targeted Therapy (Pemigatinib, Infigratinib, Ivosidenib), Immunotherapy), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), by Region, Country, Segment, and Companies, 2024-2030

Product link: <https://marketpublishers.com/r/C431599E232DEN.html>

Price: US\$ 3,980.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C431599E232DEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below  
and fax the completed form to +44 20 7900 3970